clinical trial · NCT07135323
AvertD Post-Approval Study
Prescient Medicine Holdings, Inc.·—·recruiting·n = 4,000
Opioid Use DisorderOpioid Used Disorder Risk Assessment
brief summary
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
started
Nov 15, 2024
primary completion
Nov 1, 2031
completion
Nov 1, 2031
last updated
Aug 22, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol